Position in LYEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,126,387
-$195,580 QoQ
Shares Held
56,151
+30.7% QoQ
Ownership
0.241%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 62%
Shared 0%
None 38%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026MORGAN STANLEY holds $15,440,401,210 across 521 Biotechnology names. LYEL ranks #247 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
43,571,633 | $2,090,131,227 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
51,828,325 | $1,435,644,595 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,188,881 | $1,423,962,911 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,319,329 | $1,019,366,352 | |
| 5 | TECH |
BIO-TECHNE Corp
|
8,532,873 | $445,927,935 | |
| 6 | MRNA |
Moderna, Inc.
|
8,471,263 | $430,340,154 | |
| 7 | ARGX |
Argenx SE
|
560,711 | $409,459,203 | |
| 8 | APLS |
Apellis Pharmaceuticals, Inc.
|
10,042,399 | $404,005,708 |
All Filings in LYEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,126,387 | 56,151 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,321,967 | 42,949 | Shares | Defined | 2026-05-27 | |
| 2025-09-30 | $601,202 | 37,020 | Shares | Defined | 2026-05-27 | |
| 2025-06-30 | $227,167 | 25,698 | Shares | Defined | 2025-08-15 | |
| No filing history on record for this holder in this stock. | ||||||